{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:51:42Z","timestamp":1788184302878,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40265-021-01566-2","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T10:26:36Z","timestamp":1626776796000},"page":"1397-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9366-146X","authenticated-orcid":false,"given":"Pim","family":"Aarts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-2311","authenticated-orcid":false,"given":"Koen","family":"Dudink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-5972","authenticated-orcid":false,"given":"Allard R. J. V.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-3814","authenticated-orcid":false,"given":"Kelsey R.","family":"van Straalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-4604","authenticated-orcid":false,"given":"Christine B.","family":"Ardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-660X","authenticated-orcid":false,"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-7726","authenticated-orcid":false,"given":"Hessel H.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"issue":"1","key":"1566_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18.","journal-title":"Nat Rev Dis Primers"},{"key":"1566_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677","author":"A Jfri","year":"2021","unstructured":"Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol. 2021.\u00a0https:\/\/doi.org\/10.1001\/jamadermatol.2021.1677.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1566_CR3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990\u20138.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1566_CR4","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"L Matusiak","year":"2020","unstructured":"Matusiak L. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183(6):e171\u20137.","journal-title":"Br J Dermatol"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","volume":"9","author":"A Vossen","year":"2018","unstructured":"Vossen A, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965.","journal-title":"Front Immunol"},{"issue":"5 Suppl 1","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","volume":"73","author":"E Prens","year":"2015","unstructured":"Prens E, Deckers I. of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8-11.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","volume":"164","author":"M von Laffert","year":"2011","unstructured":"von Laffert M, et al. Hidradenitis suppurativa\/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164(2):367\u201371.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1566_CR8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/all.13665","volume":"74","author":"A Vossen","year":"2019","unstructured":"Vossen A, et al. Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. Allergy. 2019;74(3):631\u20134.","journal-title":"Allergy"},{"issue":"7","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jid.2020.01.023","volume":"140","author":"A Vossen","year":"2020","unstructured":"Vossen A, et al. Lesional inflammatory profile in hidradenitis suppurativa is not solely driven by IL-1. J Invest Dermatol. 2020;140(7):1463-1466 e2.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1566_CR10","first-page":"260","volume":"179","author":"BC Melnik","year":"2018","unstructured":"Melnik BC, et al. T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection obesity smoking and autoimmune comorbidities. Br J Dermatol. 2018;179(2):260\u201372.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1566_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH van der Zee","year":"2011","unstructured":"van der Zee HH, et al. Elevated levels of tumour necrosis factor (TNF)-\u03b1 interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol. 2011;164(6):1292\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1566_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","volume":"7","author":"F Mart\u00ednez","year":"2001","unstructured":"Mart\u00ednez F, et al. Hidradenitis suppurativa and Crohn\u2019s disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7(4):323\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1566_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2133.1992.tb11830.x","volume":"126","author":"NP Burrows","year":"1992","unstructured":"Burrows NP, Jones RR. Crohn\u2019s disease in association with hidradenitis suppurativa. Br J Dermatol. 1992;126(5):523.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1566_CR14","first-page":"928","volume":"87","author":"C Gower-Rousseau","year":"1992","unstructured":"Gower-Rousseau C, et al. Hidradenitis suppurativa and Crohn\u2019s disease in two families: a significant association? Am J Gastroenterol. 1992;87(7):928.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1566_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.12104","volume":"168","author":"JL Blok","year":"2013","unstructured":"Blok JL, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243\u201352.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1566_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"12","key":"1566_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846\u201355.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1566_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","volume":"165","author":"I Miller","year":"2011","unstructured":"Miller I, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1566_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized double-blind placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1566_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","volume":"146","author":"DR Adams","year":"2010","unstructured":"Adams DR, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501\u20134.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1566_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","volume":"152","author":"V Tzanetakou","year":"2016","unstructured":"Tzanetakou V, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1566_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","volume":"138","author":"T Kanni","year":"2018","unstructured":"Kanni T, et al. MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795\u2013801.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1566_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","volume":"80","author":"A Vossen","year":"2019","unstructured":"Vossen A, et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","volume":"141","author":"JW Frew","year":"2021","unstructured":"Frew JW, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141(2):316-324 e2.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1566_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"L Matusiak","year":"2009","unstructured":"Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/bjd.17641","volume":"181","author":"A Vossen","year":"2019","unstructured":"Vossen A, et al. The anti-inflammatory potency of biologics targeting tumour necrosis factor-\u03b1 interleukin (IL)-17A IL-12\/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019;181(2):314\u201323.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1566_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","volume":"166","author":"HH van der Zee","year":"2012","unstructured":"van der Zee HH, et al. Adalimumab (antitumour necrosis factor-\u03b1) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166(2):298\u2013305.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1566_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-69 e2.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1566_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2165\/00003088-200746080-00002","volume":"46","author":"U Klotz","year":"2007","unstructured":"Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645\u201360.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1566_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/17425255.2020.1810233","volume":"16","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, et al. Metabolic pharmacokinetic and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. Expert Opin Drug Metab Toxicol. 2020;16(11):1019\u201337.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"14","key":"1566_CR31","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720\u201332.","journal-title":"Blood"},{"issue":"6","key":"1566_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","volume":"139","author":"E Witte-H\u00e4ndel","year":"2019","unstructured":"Witte-H\u00e4ndel E, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139(6):1294\u2013305.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1566_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","volume":"269","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Blocking interleukin-1\u03b2 in acute and chronic autoinflammatory diseases. J Intern Med. 2011;269(1):16\u201328.","journal-title":"J Intern Med"},{"issue":"8","key":"1566_CR34","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","volume":"140","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(8):1538-1545 e2.","journal-title":"J Invest Dermatol"},{"issue":"22","key":"1566_CR35","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503\u201319.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1566_CR36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2020.08.113","volume":"85","author":"P Aarts","year":"2021","unstructured":"Aarts P, Vossen A, van der Zee HH, Prens EP, van Straalen KR. Long-term treatment with apremilast in hidradenitis suppurativa: a 2-year follow-up of initial responders.\u00a0J Am Acad Dermatol.\u00a02021;85(1):258\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.113.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1566_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","volume":"175","author":"JR Ingram","year":"2016","unstructured":"Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175(2):263\u201372.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1566_CR38","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, et al. Assessing the validity responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434\u201342.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1566_CR39","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.15748","volume":"177","author":"CC Zouboulis","year":"2017","unstructured":"Zouboulis CC, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4) a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401\u20139.","journal-title":"Br J Dermatol"},{"key":"1566_CR40","volume-title":"Dermatologic surgery principles and practice","author":"H Hurley","year":"1989","unstructured":"Hurley H. Dermatologic surgery principles and practice. New York: Marcel; 1989."},{"issue":"3","key":"1566_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2340\/00015555-2513","volume":"97","author":"B Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th B, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group. Acta Derm Venereol. 2017;97(3):412\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1566_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/bjd.17508","volume":"180","author":"A Rondags","year":"2019","unstructured":"Rondags A, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol. 2019;180(5):1214\u201320.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1566_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1566_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical intralesional and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1566_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis evaluation and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1566_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jdv.15233","volume":"33","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, et al. Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1566_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, et al. Evidence for a \u201cwindow of opportunity\u201d in hidradenitis suppurativa treated with adalimumab: a retrospective real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1566_CR48","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","volume":"82","author":"JW Frew","year":"2020","unstructured":"Frew JW, et al. Clinical response rates placebo response rates and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol. 2020;82(5):1150\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1566_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjd.19863","volume":"185","author":"LM Prens","year":"2021","unstructured":"Prens LM, Bouwman K, Aarts P, Arends S, van Straalen KR, Dudink K, Horv\u00e1th B, Prens EP. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.\u00a0Br J Dermatol.\u00a02021;185(1):177\u201384. https:\/\/doi.org\/10.1111\/bjd.19863.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1566_CR50","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1111\/jdv.16642","volume":"34","author":"LH Gergely","year":"2020","unstructured":"Gergely LH, et al. Validity of EQ-5D-5L Skindex-16 DLQI and DLQI-R in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(11):2584\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1566_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.23736\/S0392-0488.18.06021-2","volume":"154","author":"G Vellaichamy","year":"2019","unstructured":"Vellaichamy G, et al. Patient-reported outcomes in hidradenitis suppurativa. G Ital Dermatol Venereol. 2019;154(2):137\u201347.","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"1566_CR52","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.14448","volume":"46","author":"JW Frew","year":"2021","unstructured":"Frew JW, et al. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol. 2021;46(2):306\u201313.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1566_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00575-3","volume":"22","author":"T Abdalla","year":"2021","unstructured":"Abdalla T, et al. Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series. Am J Clin Dermatol. 2021;22(2):275\u201383.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1566_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000503606","volume":"236","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa. Dermatology. 2020;236(1):25\u201330.","journal-title":"Dermatology"},{"issue":"4","key":"1566_CR55","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bjd.12713","volume":"170","author":"B Moriarty","year":"2014","unstructured":"Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170(4):986\u20137.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1566_CR56","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","volume":"81","author":"AN Oskardmay","year":"2019","unstructured":"Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1566_CR57","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, et al. High-dose high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1566_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ijd.13798","volume":"57","author":"VK Shanmugam","year":"2018","unstructured":"Shanmugam VK, et al. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57(1):62\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1566_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","volume":"135","author":"C Tang","year":"2012","unstructured":"Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112\u201324.","journal-title":"Immunology"},{"issue":"1","key":"1566_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","volume":"27","author":"BS McKenzie","year":"2006","unstructured":"McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006;27(1):17\u201323.","journal-title":"Trends Immunol"},{"issue":"1","key":"1566_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.immuni.2017.12.008","volume":"48","author":"Y Bloch","year":"2018","unstructured":"Bloch Y, et al. Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12R\u03b21. Immunity. 2018;48(1):45-58 e6.","journal-title":"Immunity"},{"issue":"9","key":"1566_CR62","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1566_CR63","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.cyto.2014.11.018","volume":"71","author":"RT Robinson","year":"2015","unstructured":"Robinson RT. IL12R\u03b21: the cytokine receptor that we used to know. Cytokine. 2015;71(2):348\u201359.","journal-title":"Cytokine"},{"issue":"10","key":"1566_CR64","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","volume":"18","author":"OJ Adedokun","year":"2020","unstructured":"Adedokun OJ, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244-2255 e9.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1566_CR65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/bjd.14338","volume":"174","author":"JL Blok","year":"2016","unstructured":"Blok JL, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839\u201346.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1566_CR66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","volume":"81","author":"RG Casseres","year":"2019","unstructured":"Casseres RG, et al. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1566_CR67","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.15368","volume":"33","author":"M Kovacs","year":"2019","unstructured":"Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e140\u20131.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1566_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5114\/reum.2019.86426","volume":"57","author":"K Banaszczyk","year":"2019","unstructured":"Banaszczyk K. Risankizumab in the treatment of psoriasis\u2014literature review. Reumatologia. 2019;57(3):158\u201362.","journal-title":"Reumatologia"},{"issue":"5","key":"1566_CR69","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/bjd.19716","volume":"184","author":"E Marques","year":"2021","unstructured":"Marques E, Arenberger P, Smetanov\u00e1 A, Gkalpakiotis S, Zimov\u00e1 D, Arenbergerov\u00e1 M. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.\u00a0Br J Dermatol.\u00a02021;184(5):966\u20137. https:\/\/doi.org\/10.1111\/bjd.19716.","journal-title":"Br J Dermatol."},{"issue":"9","key":"1566_CR70","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.4049\/jimmunol.1102576","volume":"187","author":"SL Gaffen","year":"2011","unstructured":"Gaffen SL. Life before seventeen: cloning of the IL-17 receptor. J Immunol. 2011;187(9):4389\u201391.","journal-title":"J Immunol"},{"issue":"1","key":"1566_CR71","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","volume":"19","author":"JMGR de Morales","year":"2020","unstructured":"de Morales JMGR, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1566_CR72","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ni.3742","volume":"18","author":"M Veldhoen","year":"2017","unstructured":"Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612\u201321.","journal-title":"Nat Immunol"},{"issue":"3","key":"1566_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","volume":"129","author":"RM Onishi","year":"2010","unstructured":"Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129(3):311\u201321.","journal-title":"Immunology"},{"issue":"4","key":"1566_CR74","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, et al. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1566_CR75","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/bjd.18556","volume":"182","author":"K Navrazhina","year":"2020","unstructured":"Navrazhina K, Frew JW, Krueger JG. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. Br J Dermatol. 2020;182(4):1045\u20137.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1566_CR76","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1310\/hpj5008-714","volume":"50","author":"DJ Cada","year":"2015","unstructured":"Cada DJ, et al. Secukinumab. Hosp Pharm. 2015;50(8):714\u201327.","journal-title":"Hosp Pharm"},{"issue":"1","key":"1566_CR77","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bjd.15769","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182\u20135.","journal-title":"Br J Dermatol"},{"key":"1566_CR78","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen AR, Yao Y, Thomsen SF.\u00a0Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa.\u00a0Case Rep Dermatol Med.\u00a02018;2018:8685136. https:\/\/doi.org\/10.1155\/2018\/8685136.","DOI":"10.1155\/2018\/8685136"},{"issue":"4","key":"1566_CR79","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5021\/ad.2018.30.4.462","volume":"30","author":"P Giuseppe","year":"2018","unstructured":"Giuseppe P, et al. A case of moderate hidradenitis suppurativa and psoriasis treated with secukinumab. Ann Dermatol. 2018;30(4):462\u20134.","journal-title":"Ann Dermatol"},{"issue":"2","key":"1566_CR80","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","volume":"5","author":"C Marasca","year":"2019","unstructured":"Marasca C, et al. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019;5(2):184\u20137.","journal-title":"JAAD Case Rep"},{"issue":"5","key":"1566_CR81","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"S Glatt","year":"2017","unstructured":"Glatt S, et al. First-in-human randomized study of bimekizumab a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991\u20131001.","journal-title":"Br J Clin Pharmacol"},{"key":"1566_CR82","first-page":"53","volume":"13","author":"SYD Lim","year":"2019","unstructured":"Lim SYD, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019;13:53\u201378.","journal-title":"Biologics"},{"issue":"5","key":"1566_CR83","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1566_CR84","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.19478","volume":"184","author":"JW Frew","year":"2021","unstructured":"Frew JW, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol. 2021;184(2):350\u20132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1566_CR85","doi-asserted-by":"publisher","first-page":"151899","DOI":"10.1016\/j.imbio.2019.151899","volume":"225","author":"T Chand Dakal","year":"2020","unstructured":"Chand Dakal T, et al. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders. Immunobiology. 2020;225(2):151899.","journal-title":"Immunobiology"},{"key":"1566_CR86","doi-asserted-by":"publisher","unstructured":"Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen A, van der Zee HH, Harms PW, Wasikowski R, Yee CM, Rizvi SM, Xing X, Xing E, Plazyo O, Zeng C, Patrick MT, Lowe MM, Burney RE, Kozlow JH, Cherry-Bukowiec JR, et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.\u00a0JCI Insight. 2020;5(19):e144336. https:\/\/doi.org\/10.1172\/JCI144336.","DOI":"10.1172\/JCI144336"},{"issue":"2","key":"1566_CR87","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/ajt.15661","volume":"20","author":"P Espi\u00e9","year":"2020","unstructured":"Espi\u00e9 P, et al. First-in-human clinical trial to assess pharmacokinetics pharmacodynamics safety and tolerability of iscalimab an anti-CD40 monoclonal antibody. Am J Transplant. 2020;20(2):463\u201373.","journal-title":"Am J Transplant"},{"key":"1566_CR88","doi-asserted-by":"publisher","first-page":"44449","DOI":"10.1038\/srep44449","volume":"7","author":"CM Low","year":"2017","unstructured":"Low CM, et al. The development of novel LTA(4)H modulators to selectively target LTB(4) generation. Sci Rep. 2017;7:44449.","journal-title":"Sci Rep"},{"issue":"6","key":"1566_CR89","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/thoraxjnl-2011-200234","volume":"66","author":"RJ Snelgrove","year":"2011","unstructured":"Snelgrove RJ. Leukotriene A4 hydrolase: an anti-inflammatory role for a proinflammatory enzyme. Thorax. 2011;66(6):550\u20131.","journal-title":"Thorax"},{"issue":"4","key":"1566_CR90","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1021\/acs.jmedchem.0c01955","volume":"64","author":"C Markert","year":"2021","unstructured":"Markert C, et al. Discovery of LYS006 a potent and highly selective inhibitor of leukotriene A(4) hydrolase. J Med Chem. 2021;64(4):1889\u2013903.","journal-title":"J Med Chem"},{"issue":"2","key":"1566_CR91","doi-asserted-by":"publisher","first-page":"e144336","DOI":"10.1172\/JCI144336","volume":"131","author":"M Elias","year":"2021","unstructured":"Elias M, Zhao S, Le HT, Wang J, Neurath MF, Neufert C, Fiocchi C, Rieder F. IL-36 in chronic inflammation and fibrosis - bridging the gap? J Clin Invest.\u00a02021;131(2):e144336.\u00a0https:\/\/doi.org\/10.1172\/JCI144336.","journal-title":"J Clin Invest."},{"issue":"2","key":"1566_CR92","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.18632\/oncotarget.22814","volume":"9","author":"L Ding","year":"2018","unstructured":"Ding L, et al. IL-36 cytokines in autoimmunity and inflammatory disease. Oncotarget. 2018;9(2):2895\u2013901.","journal-title":"Oncotarget"},{"issue":"3","key":"1566_CR93","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.16019","volume":"178","author":"S Hessam","year":"2018","unstructured":"Hessam S, et al. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol. 2018;178(3):761\u20137.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1566_CR94","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1566_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","volume":"20","author":"AA Zarrin","year":"2021","unstructured":"Zarrin AA, et al. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20(1):39\u201363.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1566_CR96","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jid.2019.09.009","volume":"140","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, et al. Role of the complement pathway in inflammatory skin diseases: a focus on hidradenitis suppurativa. J Invest Dermatol. 2020;140(3):531-536 e1.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1566_CR97","first-page":"413","volume":"179","author":"T Kanni","year":"2018","unstructured":"Kanni T, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179(2):413\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1566_CR98","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjd.18877","volume":"183","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183(1):176\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1566_CR99","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.4049\/jimmunol.0900305","volume":"183","author":"MW Nasser","year":"2009","unstructured":"Nasser MW, et al. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol. 2009;183(5):3425\u201332.","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"1566_CR100","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/exd.14338","volume":"30","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(Suppl 1):8\u201317.","journal-title":"Exp Dermatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01566-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T07:36:03Z","timestamp":1699256163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01566-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01566-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"28 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PA, KD, ARDVV, KvS and CBA have no conflicts of interest to declare. EPP has acted as a consultant, speaker, principal investigator or received grants from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Janssen\u2010Cilag, Novartis, Pfizer and UCB. HHvdZ has been an advisory board member for AbbVie, InflaRX, and a speaker for Galderma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HHZ was invited author for this article, PA and KD performed the literature search and data analysis. PA, KD, ARJVV, KRvS, CBA, EPP and HHvdZ wrote the text and critically revised the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}